Foxchart.com
Navidea Biopharmaceuticals, Inc. (NAVB)
0.0365  0.001 (2.82%)  03-28 15:06
Open: 0.033
High: 0.04133
Low: 0.033
Volume: 64,218
Market Cap: 4(M)
PE Ratio: -0.18
Exchange: American Stock Exchange
Industry: Biotechnology
Sector: Healthcare
Technical analysis
Rating Flag Rating Flag Rating Flag Rating Flag Rating Flag
sell buy
Resistance 2: 0.05
Resistance 1: 0.04
Pivot price: 0.04
Support 1: 0.03
Support 2: 0.03
52w High: 0.32955
52w Low: 0.021
Watchlist
MSFT0 (0%)
TWTR0 (0%)
BAC0 (0%)
AMZN0 (0%)
FB0 (0%)
GM0 (0%)
Zoom in Zoom out
Draw lines
Horizontal lines
Parallel lines
Fibonacci lines
Remove studies
Shot and share

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.

Financials
EPS -119300.000
Book Value -0.200
PEG Ratio 0.00
Gross Profit 0.000
Profit Margin (%) 0.00
Operating Margin (%) -1.00
Return on Assets (ttm) 678.0
Return on Equity (ttm) 791.0
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
×
Share on Facebook Tweet this page

Foxchart international:  |  United States  |  Canada  |  United Kingdom  |  Australia  |  New Zealand  |  Singapore  |  India

©Foxchart.com All Rights Reserved. Foxchart.com | United States NYSE NASDAQ AMEX stock markets, stock quotes and stock technical analysis charts. Data and information is provided for informational purposes only, is not intended for trading purposes and is not investment advice. Neither Foxchart.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Market data provided by: IEX